Bilirubin ameliorates metabolic dysregulation by targeting the HSP90β/SREBPs signaling axis to improve insulin resistance and mitigate ectopic lipid deposition

Abstract

Aim: Sterol regulatory element-binding proteins (SREBPs) are key transcription factors driving de novo lipid synthesis (DNL) and associated metabolic disorders. This study aims to investigate whether bilirubin, a potential SREBP inhibitor, alleviates lipid accumulation and insulin resistance by targeting the HSP90β/SREBP pathway.

Methods:In vitro, HL-7702 cells were treated with bilirubin to assess lipid-lowering effects and SREBP-related gene expression. In vivo, high-fat diet (HFD)-induced obese mice received bilirubin intervention for 6 weeks. Lipid profiles, insulin sensitivity, hepatic SREBP protein levels, and downstream gene expression were analyzed. Mechanistic studies focused on HSP90β activity modulation by bilirubin.

Results: Bilirubin significantly reduced lipid accumulation in HL-7702 cells and downregulated SREBPs and their target genes. In HFD-fed mice, bilirubin attenuated obesity, hepatic steatosis, and insulin resistance, accompanied by suppressed SREBP protein levels and expression of target genes. Mechanistically, bilirubin inhibited SREBP activation by targeting HSP90β.

Conclusion: Bilirubin ameliorates metabolic syndrome via the HSP90β/SREBP axis, providing a novel therapeutic strategy for lipid metabolism disorders and insulin resistance. These findings highlight bilirubin’s potential as a pharmacological agent against metabolic diseases.

Keywords

Bilirubin / metabolic syndrome / SREBPs / HSP90β

References

[1] Alembagheri A,Choopani R.The role of selected medicinal plants from Iranian traditional medicine for the treatment of fatigue in metabolic syndrome.Tradit Med Res2023;8:23

[2] Kalisz K,Itani M,Venkatesh SK.Multimodality imaging in metabolic syndrome: state-of-the-art review.Radiographics2024;44:e230083

[3] Davids SF,Peer N,Kengne AP.Changes in obesity phenotype distribution in mixed-ancestry South Africans in cape town between 2008/09 and 2014/16.Front Endocrinol2019;10:753 PMCID:PMC6851026

[4] Shen S,Gu L.G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases.Acta Materia Medica2024;3:31-45

[5] Schmid A,Schäffler A.The emerging role of bile acids in white adipose tissue.Trends Endocrinol Metab2023;34:718-34

[6] Gálvez I,Martín-Cordero L,Hinchado MD.The influence of obesity and weight loss on the bioregulation of innate/inflammatory responses: macrophages and immunometabolism.Nutrients2022;14:612 PMCID:PMC8840693

[7] Fu M,Yu H.Metabolomics investigation on antiobesity effects of Corydalis bungeana on high-fat high-sugar diet-induced obese rats.Chin Herb Med2022;14:414-21 PMCID:PMC9476812

[8] Hugelshofer M,Schaer CA.Haptoglobin administration into the subarachnoid space prevents hemoglobin-induced cerebral vasospasm.J Clin Invest2019;129:5219-35 PMCID:PMC6877320

[9] Walter ERH,Mason JC,Long NJ.A coumarin-porphyrin FRET break-apart probe for heme oxygenase-1.J Am Chem Soc2021;143:6460-9 PMCID:PMC8154531

[10] Vuerich M,Graham JJ.Blockade of PGK1 and ALDOA enhances bilirubin control of Th17 cells in Crohn’s disease.Commun Biol2022;5:994 PMCID:PMC9492699

[11] Creeden JF,Stec DE.Bilirubin as a metabolic hormone: the physiological relevance of low levels.Am J Physiol Endocrinol Metab2021;320:E191-207 PMCID:PMC8260361

[12] Wang S,Zhou Z.Circadian clock gene bmal1 regulates bilirubin detoxification: a potential mechanism of feedback control of hyperbilirubinemia.Theranostics2019;9:5122-33 PMCID:PMC6691581

[13] Wang F,Ren L.The effect of silibinin on protein expression profile in white adipose tissue of obese mice.Front Pharmacol2020;11:55 PMCID:PMC7059093

[14] Chen W,Fazakerley DJ.Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance.Redox Biol2021;47:102152 PMCID:PMC8498001

[15] Cheng C,Li Z.Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth.Nat Metab2022;4:575-88 PMCID:PMC9177652

[16] Zhang C,Jing H.SAK-HV triggered a short-period lipid-lowering biotherapy based on the energy model of liver proliferation via a novel pathway.Theranostics2017;7:1749-69 PMCID:PMC5436525

[17] DeBose-Boyd RA.SREBPs in lipid metabolism, insulin signaling, and beyond.Trends Biochem Sci2018;43:358-68 PMCID:PMC5923433

[18] Podszun MC,Lingala S.Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis.Redox Biol2020;37:101710 PMCID:PMC7494510

[19] Shimano H.SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology.Nat Rev Endocrinol2017;13:710-30

[20] Liu Y,Shen L.Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.J Control Release2020;323:431-41 PMCID:PMC8601127

[21] Talaei S,Asadi A,Sheervalilou R.Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.Chem Biol Drug Des2019;93:760-86

[22] Zheng ZG,Liu XX.Inhibition of HSP90β improves lipid disorders by promoting mature SREBPs degradation via the ubiquitin-proteasome system.Theranostics2019;9:5769-83 PMCID:PMC6735373

[23] Kuan YC,Shibata T.Heat shock protein 90 modulates lipid homeostasis by regulating the stability and function of sterol regulatory element-binding protein (SREBP) and SREBP cleavage-activating protein.J Biol Chem2017;292:3016-28 PMCID:PMC5314195

[24] Mirhadi E,Kesharwani P.Utilizing stimuli-responsive nanoparticles to deliver and enhance the anti-tumor effects of bilirubin.Biotechnol Adv2024;77:108469

[25] Bortolussi G,Ten Bloemendaal L.Long-term effects of biliverdin reductase a deficiency in ugt1^-/- mice: impact on redox status and metabolism.Antioxidants2021;10:2029 PMCID:PMC8698966

[26] Li Y,Ye T,Xia D.Physiological concentrations of bilirubin control inflammatory response by inhibiting NF-κB and inflammasome activation.Int Immunopharmacol2020;84:106520

[27] Bianco A,Capková N.The extent of intracellular accumulation of bilirubin determines its anti- or pro-oxidant effect.Int J Mol Sci2020;21:8101 PMCID:PMC7663266

[28] Vitek L,Stec DE.The physiology of bilirubin: health and disease equilibrium.Trends Mol Med2023;29:315-28 PMCID:PMC10023336

[29] Adin CA.Bilirubin as a therapeutic molecule: challenges and opportunities.Antioxidants2021;10:1536 PMCID:PMC8532879

[30] Gordon DM,Kipp ZA.Identification of binding regions of bilirubin in the ligand-binding pocket of the peroxisome proliferator-activated receptor-A (PPARalpha).Molecules2021;26:2975 PMCID:PMC8157031

[31] Kim TW,Jung W.Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells.J Control Release2021;331:74-84

[32] Tomaro ML.Bilirubin: its role in cytoprotection against oxidative stress.Int J Biochem Cell Biol2002;34:216-20

[33] Yang K,Woodhead JL.Systems pharmacology modeling of drug-induced hyperbilirubinemia: differentiating hepatotoxicity and inhibition of enzymes/transporters.Clin Pharmacol Ther2017;101:501-9 PMCID:PMC5367379